SCHEDULE: Foresite Capital Amends Maze Therapeutics Stake
Amendment to Beneficial Ownership Report
Foresite Capital entities and James Tananbaum report a combined 1.4% beneficial ownership in Maze Therapeutics, Inc. common stock.
Summary
- Foresite Capital Fund IV, L.P. (FCF IV) beneficially owns 522,657 shares of Maze Therapeutics, Inc. common stock, representing 1.2% of the class.
- Foresite Capital Management IV, LLC (FCM IV), as the general partner of FCF IV, is deemed to have sole voting and dispositive power over FCF IV's 522,657 shares, equating to 1.2% ownership.
- Foresite Capital Fund V, L.P. (FCF V) beneficially owns 86,291 shares of Maze Therapeutics, Inc. common stock, representing 0.2% of the class.
- Foresite Capital Management V, LLC (FCM V), as the general partner of FCF V, is deemed to have sole voting and dispositive power over FCF V's 86,291 shares, equating to 0.2% ownership.
- James Tananbaum, as the managing member of both FCM IV and FCM V, is deemed to have sole voting and dispositive power over a total of 608,948 shares (522,657 from FCF IV + 86,291 from FCF V), representing an aggregate of 1.4% of the class.
- The percentage of class is calculated based on 43,850,884 shares of Common Stock outstanding as of August 6, 2025, as reported in Maze Therapeutics' Form 10-Q filed on August 12, 2025.
- The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor. While not directly impacting company performance, the continued holding by a specialized healthcare investor like Foresite Capital can be seen as a neutral to slightly positive signal regarding their long-term view of Maze Therapeutics.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Management Comments
- NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a biotechnology company. It reflects an existing investment position rather than a new strategic move or industry trend.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming Foresite Capital's stake in Maze Therapeutics.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-08-06 | Date as of which 43,850,884 Common Stock of Maze Therapeutics, Inc. were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-08-12 | Date Maze Therapeutics, Inc. filed its Form 10-Q with the SEC. |
| 2025-09-30 | Date of event which requires the filing of this statement. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 1 was signed by the Reporting Persons. |
Keywords
Maze Therapeutics, Foresite Capital, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.